Navigation Links
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
Date:12/10/2013

ts' first treatment at OSU (OSU Tx1), 16% (n=27), 33% (n=58), and 51% (n=89) of pts received an ibrutinib-based therapy, cyclin-dependent kinase inhibitor-based therapy (CDKi), or other therapies (O), respectively.

The ORR was significantly different among groups at 56%, 45%, and 24% in the ibrutinib, CDKi, and O groups, respectively. 12-month progression free survival (PFS) estimates were 77%, 38%, and 17% in the ibrutinib, CDKi, and O groups, respectively. 12-month overall survival (OS) estimates were 81%, 78%, and 58%. Notably, age did not correlate with response, PFS, or OS.

-ORAL PRESENTATION- CLL Abstract #673:
Single Agent Ibrutinib Achieves Equal Responses in CLL Patients With and Without Deletion 17p
Mohammed Farooqui, DO, National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda, MD

This phase 2, single center, study of ibrutinib as a single-agent aimed to address the role of ibrutinib in the treatment of CLL patients with del 17p, regardless of their prior treatment history. The study enrolled 29 patients with del 17p, and 24 elderly patients without del 17p (NL 17p). Fifteen of the del 17p patients and eight of the NL 17p patients were treatment naive. The primary endpoint of the study was response after 6 months, assessed by computed tomography (CT) scans, bone marrow biopsies, and routine clinical and laboratory studies.

At six months, 47 patients were evaluable. Of the patients with del 17p, 53% achieved a PR and 43% achieved a PRL, compared to 82% PR and 9% PRL among the NL 17p patients. The apparent difference in response rates is due to slower clearance of the treatment-induced lymphocytosis in the del 17p patients; however, the clinical benefit and disease control in all tissue sites was equal for both cohorts of patients. Twenty-month PFS was 100% in the NL 17p cohort, and 85% in the del 17p cohort.

The
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. WuXi PharmaTech to Partner with Pharmacyclics
2. Pharmacyclics Reports Third Quarter 2013 Results
3. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
4. Pharmacyclics Reports Second Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
6. Pharmacyclics Reports First Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
8. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. Pharmacyclics, Inc. Prices Public Offering of Common Stock
11. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Calif. , April 23 PRO-DEX, INC. (Nasdaq: PDEX ) ... period ended March 31, 2010 on Thursday, April 29, 2010 ... , , ... Eastern Time ( 1:30 Pacific Time ) to discuss operating performance for ...
... VIENNA , April 23, 2010 ... progressed to phase II clinical testing.,It may therefore be possible ... 2012. Indeed the start of this efficacy study comes only ... The company,is active in several disease areas and is currently ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2010 Third Quarter Financial Results Conference Call and Webcast 2Pro-Dex, Inc. Announces Fiscal 2010 Third Quarter Financial Results Conference Call and Webcast 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 2AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 4
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... One of the most popular vaccine brands for ... doctors may be overlooking some cost factors when choosing ... more expensive option, according to a new study by ... to administer can be driven by numerous factors," says ... a professor of computer science and of mathematics at ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Cardiac Science (Nasdaq: CSCX ), ... rehabilitation, and informatics products, today announced that it ... Association (WBBA) 2009 Invest Northwest CEO and Investor ... in Seattle. Michael Matysik, senior vice president and ...
... Nausea and Vomiting (PONV)CORONA DEL MAR, Calif., March 11 ... patient,s oxygen status known on a beat-by-beat basis. Not ... say that all patients should have this monitor. No ... ASA Newsletter on their web site between 1983 and ...
... Interactive, Inc. was accepted as an affiliate member of ACA International ... as the American Collectors Association. , ... (Vocus) March ... Ave Ste 100, Plantation, FL 33324-3223, was accepted as an affiliate ...
... Corporation with a Scalable, Powerful System in Support of Patient Safety ... ... Francisco, CA (PRWEB) March 11, 2009 -- The Florida Patient Safety ... certified as a Patient Safety Organization (PSO), has chosen Quantros ...
... a toy drive at Build-A-Bear during annual team-building event , ... ... Cydcor , the leading provider of outsourced, face-to-face sales teams, hosted ... annual corporate kick-off meeting. , ,About 70 participating Cydcor ...
... BC Decker Inc, publisher of the acclaimed general surgical reference, ACS ... MD, FACS as the new Editor-in-Chief , ... Philadelphia, ... the acclaimed general surgical reference, ACS Surgery, is honored to announce ...
Cached Medicine News:Health News:Cardiac Science to Present at the Eighth Annual Invest Northwest Conference 2Health News:American Society of Anesthesiologists (ASA) - Myths About 'Never Ending Pursuit of Patient Safety and Satisfaction' Debunked 2Health News:Business Becomes Affiliate Member of International Trade Association 2Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 2Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 3Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 4Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 5Health News:Cydcor Builds Bears and Bonds in Special Charity Event Benefitting Childrens Hospital Los Angeles 2Health News:New Editor, New Vision for ACS Surgery 2Health News:New Editor, New Vision for ACS Surgery 3
... For the qualitative ... falciparum (P.f) antigen and an ... all four species of malaria:plasmodium ... Plasmodium ovale (P.o) and Plasmodium ...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... combines full 0.25 mm pb protection ... drape material that can be placed ... the clinician and the source of ... must be in very close proximity ...
... only insulin pen with a memory. HumaPen MEMOIR records ... doses (including priming doses). You can see exactly when ... MEMOIR, you simply "dial" your dose by turning the ... after initial set-up. If you dial too many units, ...
Medicine Products: